What it is
Omega-3s contribute to membrane structure and signaling. ALA is essential and its conversion to EPA and DHA is limited; formulation matters when interpreting clinical effects.
Evidence basis: Human clinical evidence
At a glance
What it is, why people use it, the evidence, and what to know before trying it.
Why people use it
- Omega-3 nutrient intake
Evidence at a glance
Nutritional roles are established, but an unspecified omega-3 capsule cannot inherit the outcomes of a particular prescription EPA drug or fish-oil trial. Amount and chemical form must be known to assess a treatment claim.
Confidence: moderate
Safety & interactions
Known side effects, interactions and use limits from reviewed sources.
Supplements may cause gastrointestinal effects. High-dose EPA/DHA trials found increased atrial-fibrillation risk in cardiovascular-risk populations; anticoagulant use warrants review. These findings are not identical for every omega-3 form.
Forms and variants
This review does not automatically apply to:
- Assumed fish oil
- Prescription icosapent ethyl
- A specified algal EPA/DHA blend
Seen in protocols
Public protocols that include Omega-3 fatty acids (form unspecified). Open one to see the full context and source.
Explore from here
Continue into interventions that appear alongside this one.